Loading...
The combination of dolutegravir (a promising once-daily unboosted integrase inhibitor) and etravirine (a second-generation nonnucleoside reverse transcriptase inhibitor) is a potentially attractive option for patients infected with multidrug-resistant HIV. However, possible interactions between the two drugs, which share similar metabolic pathways, are still being evaluated.
Two open-label crossover studies were recently conducted among HIV-uninfected men (33 total) to evaluate the pharmacokinetics (PK) of dolutegravir in three scenarios: when it is administered alone, when it is administered only with etravirine, and when it is administered with etravirine plus either ritonavir-boosted darunavir or lopinavir/ritonavir. Both studies were con…